TLDR PMGC rises 4.43% as NorthStrive expands its patent strategy into space health. NorthStrive files patents for EL-22 and EL-32 targeting microgravity muscle loss. EL-22 targets myostatin while EL-32 targets myostatin and activin A pathways. New filings cover dosing, delivery m...